Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report.
Publication Title
Case Rep Oncol
Document Type
Article
Publication Date
1-1-2025
Keywords
Bispecific T-cell engager; Case report; Chimeric antigen receptor T-cell therapy; Non-Hodgkin lymphoma.: alaska; pamc
Abstract
INTRODUCTION: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses considerable treatment challenges, with disheartening odds of long-term survival. Numerous strategies exist, including non-cross-resistant combination chemoimmunotherapy regimens, autologous stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, but some patients are not appropriate candidates or cannot sustain response to treatment. Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, has been given accelerated approval by the US Food and Drug Administration for relapsed or refractory DLBCL.
CASE PRESENTATION: We present the case of a 61-year-old male diagnosed with stage 4 "double-hit" DLBCL with
CONCLUSION: T-cell engager therapies, such as epcoritamab, can play a role in managing patients with refractory DLBCL, including those refractory to CAR T-cell therapy.
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Hematology
DOI
10.1159/000545372
